SURMOUNT-OSA

Lifestyle & Health slider
FDA Approves Tirzepatideas the First and Only Prescription Medicine for Moderate-to-Severe Obstructive Sleep Apnea in Adults with Obesity

by Karine Ayoub January 13, 2025

by Karine Ayoub January 13, 2025

Averaging up to 20% of weight loss, adults taking Tirzepatide had at least 25…

0 Facebook Twitter Pinterest Email

Weekly Notification

Bulletin’s Archive

Search Bulletins

Tags

Abu Dhabi Ports American University of Beirut American University of Sharjah (AUS) AUB aubmc Bank Audi Blom Bank Byblos Bank cannes lions Corona Virus (COVID-19) COVID-19 Corona Elie Saab Emirates Ericsson Garena Free Fire Gartner Global Village Globemed Grohe Huawei Hyundai Kandima Maldives Kia Kia Corporation LAU Medical Center Rizk Hospital LG LG Electronics Maserati Mastercard National Commission for Lebanese Women NISSAN PRCA MENA Ralph & Russo Ramadan Rebirth Beirut Salesforce Samsung SAP Starzplay Tony Ward UN UNICEF United Nations VFS Global Zuhair Murad

THE BULLETIN

All press releases and company news, brochures, logos, videos, images, and brands are property of their respective owners and not the bulletin.
All press releases and company news, brochures, logos, videos, images, and brands references used in this website are for identification and informational purposes only.
Use of these press releases and company news, brochures, logos, videos, images, and brands does not imply endorsement by, sponsorship by, or affiliation with the bulletin.

JOIN US

About us
Contact us
HOME

Keep in touch

Facebook

SURMOUNT-OSA

FDA Approves Tirzepatideas the First and Only Prescription Medicine for Moderate-to-Severe Obstructive Sleep Apnea in Adults with Obesity